...
首页> 外文期刊>Methods: A Companion to Methods in Enzymology >Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers
【24h】

Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers

机译:免疫组织化学对生物标志物发现的抗体验证:学术和药物组织病理学研究人员联盟的建议

获取原文
获取原文并翻译 | 示例

摘要

As biomarker discovery takes centre-stage, the role of immunohistochemistry within that process is increasing. At the same time, the number of antibodies being produced for "research use" continues to rise and it is important that antibodies to be used as biomarkers are validated for specificity and sensitivity before use. This guideline seeks to provide a stepwise approach for the validation of an antibody for immunohistochemical assays, reflecting the views of a consortium of academic and pharmaceutical based histopathology researchers. We propose that antibodies are placed into a tier system, level 1-3, based on evidence of their usage in immunohistochemistry, and that the degree of validation required is proportionate to their place on that tier. (C) 2014 The Authors. Published by Elsevier Inc.
机译:由于生物标志物发现采取中心阶段,免疫组化在该过程中的作用正在增加。 同时,为“研究用途”产生的抗体数继续上升,重要的是在使用前验证用作生物标志物的抗体以进行验证以进行特异性和敏感性。 该指南寻求提供用于免疫组织化学分析的抗体验证的逐步方法,反映了学术和药物组织病理学研究人员的联盟的视图。 我们提出基于其在免疫组织化学的使用证据,将抗体置于1-3级,1-3级,并且所需的验证程度与他们在该层上的位置比例。 (c)2014年作者。 elsevier公司发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号